Por: RTTNews Health December 06, 2022
Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group.According to the companies, high level of respiratory illnesses are currently circulating among children under 5 years of age, and the... + full article
Ars Technica USA Science December 10, 2022
Navigate Filter by topic Settings Front page layout Site theme - Dec 9, 2022 11:08 pm UTC / Reisa Lancaster RN, left, administers the Covid-19 vaccine to 14 month old Ada Hedge, center, being comforted by mom Sarah Close and dad Chinmay Hedge, right at Children's National... + más
FDA greenlights bivalent vaccines for children as young as 6 months old | Politico
New COVID booster authorization will sway parents to get young kids vaccinated, FDA vaccine chief hopes | ABC News
ABC News USA Health December 09, 2022
Dr. Peter Marks, the Food and Drug Administration's vaccine chief, said he is well aware that COVID-19 booster uptake might be low for the latest shot, for young children over 6 months old, but he told ABC News that he's hopeful increased access may also lead to some... + más
FDA authorizes Novavax Covid-19 vaccine for use as a first booster shot | CNN
FDA Authorizes Novavax's Covid Shots as Mix-And-Match Booster to Pfizer Or Moderna | NBC 6 South Florida
Politico USA Health December 08, 2022
The FDA on Thursday authorized emergency use of updated bivalent Covid-19 vaccines for children as young as 6 months old. The move to authorize bivalent shots made by Pfizer-BioNTech and Moderna comes as Covid-19 infections in the United States tick up amid the most intense flu... + más
Kids 5-11 can now get the bivalent, BA.5-targeting COVID booster | Ars Technica
FDA authorizes bivalent COVID-19 boosters for children as young as 6 months | WGN-TV
CNBC USA Health December 06, 2022
Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021.Dado Ruvic Reuters has rejected allegations made by rival that its Covid-19 vaccine is a copy, accusing the Boston biotech company of... + más
Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate
Moderna is suing Pfizer over its coronavirus vaccine | The Verge
CNBC USA Health November 02, 2022
Pfizer CEO Albert Bourla talks during a press conference with European Commission President after a visit to oversee the production of the Pfizer-BioNtech Covid-19 vaccine at the factory of US pharmaceutical company Pfizer, in Puurs, on April 23, 2021.John Thys AFP Getty Images... + más
Pfizer raises 2022 earnings guidance, beats third-quarter expectations | CNBC
Pfizer climbs on strong Q3 results, raised outlook | MarketWatch
Newsweek USA Health November 02, 2022
Pfizer announced positive trial results on Tuesday for a vaccine designed to help protect against the respiratory syncytial virus, or RSV, potentially setting up the company to have the first shot of its kind to be approved against the virus.The exact timeline for the vaccine... + más
Strong RSV vaccine data lifts hopes after years of futility | 10 WBNS
Pfizer says study shows vaccinating pregnant women protects newborns from RSV | ABC7
CNN USA Health November 01, 2022
CNN — Pfizer says it has enough promising data on its respiratory syncytial virus, or RSV, vaccine designed to protect newborns that it will end enrollment in the study and submit for US Food and Drug Administration approval by the end of the year. RSV is a common... + más
Pfizer announces promising developments for 1st maternal RSV vaccine | ABC News
When Will the RSV Vaccine be Available? Pfizer Jab Shows 'Positive' Results | Newsweek
About iurex | Privacy Policy | Disclaimer |